114873-11-9

Basic information

• Product Name: BOC-D-3-Fluorophe
• Synonyms: BOC-(R)-2-AMINO-3-(3'-FLUOROPHENYL)PROPANOIC ACID;BOC-3-FLUORO-D-PHE;BOC-3-FLUORO-D-PHENYLALANINE;BOC-M-FLUORO-D-PHE-OH;BOC-D-PHE(3-F)-OH;BOC-D-PHE(M-F)-OH;BOC-D-3-FLUOROPHE;BOC-D-3-FLUOROPHENYLALANINE
• CAS NO: 114873-11-9
• Molecular Formula: C14H18FNO4
• Molecular Weight: 283.3
• Product Categories: Amino Acids;Phenylalanine analogs and other aromatic alpha amino acids;Amino Acid Derivatives;Peptide;a-amino
• Mol File: 114873-11-9.mol

Chemical Properties

• Melting Point: 75-79 °C
• Boiling Point: 425 °C at 760 mmHg
• Flash Point: 210.8 °C
• Appearance: Off-white/Powder
• Density: 1.1918 (estimate)
• Vapor Pressure: 5.57E-08mmHg at 25°C
• Storage Temp.: Keep Cold
• PKA: 3.82±0.10(Predicted)
• CAS DataBase Reference: BOC-D-3-Fluorophe(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-D-3-Fluorophe(114873-11-9)
• EPA Substance Registry System: BOC-D-3-Fluorophe(114873-11-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 24/25
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 114873-11-9(Hazardous Substances Data)

Usage

Chemical Properties

off-white powder

InChI:InChI=1/C14H18FNO4/c1-14(2,3)20-13(19)16-11(12(17)18)8-9-5-4-6-10(15)7-9/h4-7,11H,8H2,1-3H3,(H,16,19)(H,17,18)/p-1/t11-/m1/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 19883-77-3 L-3-fluorophenylalanine 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 1073-06-9 3-fluorobromobenzene 
• 768-35-4 3-fluorophenylboronic acid 
• 110117-84-5 (R)-2-amino-3-(3-fluorophenyl)propionic acid 
• 123-91-1 1,4-dioxane 
• 456-88-2 3-fluorophenylalanine 

Downstream Products

• 1227360-99-7 C₂₁H₂₃BrFN₃O₄ 
• 1430058-15-3 C₃₅H₂₇FN₄O₃ 
• 1430058-14-2 C₃₀H₂₂FN₅O₃ 
• 1430057-35-4 2-[(1S)-2-amino-1-(3-fluorobenzyl)ethyl]-6-(4-chloro-1-methyl-1H-pyrazol-5-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one 
• 1430058-68-6 2-[(2S)-2-(6-chloro-3-oxo-1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione 
• 1430056-70-4 5-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-[(1S)-1-(3-fluorobenzyl)-2-(methylamino)ethyl]isoindolin-1-one 
• 1430058-22-2 (2S)-2-[5-(4-chloro-1-methyl-1H-pyrazol-5-yl)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]-3-(3-fluorophenyl)propanal 
• 1430058-19-7 5-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-[(1S)-1-(3-fluorobenzyl)-2-hydroxyethyl]isoindolin-1-one 
• 1430058-17-5 5-bromo-2-[(1S)-1-(3-fluorobenzyl)-2-hydroxyethyl]isoindolin-1-one 
• 1430056-55-5 2-[(1S)-2-amino-1-(3-fluorobenzyl)ethyl]-5-(4-phenyl-1-methyl-1H-pyrazol-5-yl)isoindolin-1-one 
• 1430056-54-4 2-[(1S)-2-amino-1-(3-fluorobenzyl)ethyl]-5-(4-cyano-1-methyl-1H-pyrazol-5-yl)isoindolin-1-one 
• 1430056-53-3 2-[(1S)-2-amino-1-(3-fluorobenzyl)ethyl]-5-(4-bromo-1-methyl-1H-pyrazol-5-yl)isoindolin-1-one 
• 1430058-13-1 2-[(2S)-2-[5-(4-bromo-1-methyl-1H-pyrazol-5-yl)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione 
• 1430056-52-2 2-[(1S)-2-amino-1-(3-fluorobenzyl)ethyl]-5-(4-fluoro-1-methyl-1H-pyrazol-5-yl)isoindolin-1-one 

Relevant articles and documents

OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO

Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R3, R4, R5, R6, R8, m and n are as defined herein. Such compounds modulate the opioid receptor, particulare the mu-opioid receptor (MOR) and/or the kappa-opioid receptor (KOR), and/or the delta-opioid receptor (DOR). Products containing such compounds, as well as methods for their use and preparation, are also provided.

Chirality-Driven Mode of Binding of α-Aminophosphonic Acid-Based Allosteric Inhibitors of the Human Farnesyl Pyrophosphate Synthase (hFPPS)

Thienopyrimidine-based allosteric inhibitors of the human farnesyl pyrophosphate synthase (hFPPS), characterized by a chiral α-aminophosphonic acid moiety, were synthesized as enantiomerically enriched pairs, and their binding mode was investigated by X-ray crystallography. A general consensus in the binding orientation of all (R)- and (S)-enantiomers was revealed. This finding is a prerequisite for establishing a reliable structure-activity relationship (SAR) model.

New reagent for the introduction of Boc protecting group to amines: Boc-OASUD

A new reagent, tert-butyl (2,4-dioxo-3-azaspiro [5,5] undecan-3-yl) carbonate (Boc-OASUD) for the preparation of N-Boc-amino acids is described. The Boc-OASUD reacts with amino acids and their esters at room temperature in the presence of a base and gives N-Boc-amino acids and their esters in good yields and purity. Introduction of the Boc group takes place without racemization. The Boc-OASUD, being a solid and more stable, is a better alternative to di-tert-butyl dicarbonate which is low melting and has to be dispensed in plastic containers than glass because of its poor stability.

QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS

The invention is directed to quinazoline compounds that can inhibit the bioactivity of one or more kinase enzymes, including a Rho kinase, an AKT kinase, a p70S6K kinase, a LIM kinase, an IKK kinase, a Fit kinase, an Aurora kinase, or a Src kinase, or any combination thereof; to methods of use of those compounds; and to methods of preparation of those compounds. The inventive compounds can be used in the treatment of malconditions including cardiovascular disease, neurogenic pain, hypertension, atherosclerosis, angina, stroke, arterial obstruction, peripheral arterial disease, erectile dysfunction, acute and chronic pain, dementia, Alzheimer's disease, Parkinson's disease, neuronal degeneration, asthma, amyotrophic lateral sclerosis, spinal cord injury, rheumatoid arthritis, osteoarthritis, osteoporosis, psoriasis, cerebral vasospasm, open angle glaucoma, multiple sclerosis, pulmonary hypertension, acute respiratory distress syndrome, inflammation, diabetes, urinary organ diseases and benign prostatic hypertrophy (BPH), metastasis, cancer, glaucoma, ocular hypertension, retinopathy, autoimmune disease, viral infection, or myocardial pathology.

HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME AND THEIR PHARMACEUTICAL USES

This invention relates to a novel series of chemical compounds useful as Human immunodeficiency Virus (HIV) protease inhibitors and to the use of such compounds as antiviral agents. The invention further relates to pharmaceutical compositions containing s

HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis

The present invention concerns processes for preparing compounds of formula (I-H), or a prodrug, pharmaceutically active metabolite, or pharmaceutically active salt or solvate thereof, which are useful as inhibitors of the HIV protease enzyme.

Studies of Neurokinin Antagonists. 4. Synthesis and Structure-Activity Relationships of Novel Dipeptide Substance P Antagonists: N2--L-prolyl>-N-methyl-N-(phenylmethyl)-3-(2-naphthyl)-L-alaninamide and Its Related Compounds

As an extension of our studies on discovering a novel substance P (SP) antagonist, we modified the previously reported dipeptide, N2-2-(1H-indol-3-ylcarbonyl)-L-lysyl>-N-methyl-N-(phenylmethyl)-L-phenylalaninamide (2b).The lysine part in 2b was first optimized to a (2S,4R)-hydroxyproline derivative (3h), which is 2-fold more potent than 2b in SP binding assay using guinea pig lung membranes.Next we modified the 1H-indol-3-ylcarbonyl part in 3h.Introduction of a methyl group at the indole nitrogen enhanced the oral activity, while retaining the binding activity.Finally, we modified the phenylalanine part to culminate in the most potent compound 7k (FK888), which is a potent SP antagonist with NK1 selectivity as well as oral activity.

Transport of antimicrobial agents using peptide carrier systems: Anticandidal activity of m-fluorophenylalanine-peptide conjugates

A series of di- and tripeptides containing D- and L-m-fluorophenylalanine was prepared and tested in vitro for the ability to inhibit the growth of the yeast Candida albicans. The results demonstrate that peptides containing L-m-fluorophenylalanine inhibi